Service interruption on Monday 11 July from 12:30 to 13:00: all the sites of the CCSD (HAL, Epiciences, SciencesConf, AureHAL) will be inaccessible (network hardware connection).
Skip to Main content Skip to Navigation
Journal articles

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.

Abstract : ABSTRACT: The ASXL1 gene is one of the most frequently mutated genes in malignant myeloid diseases. The ASXL1 protein belongs to protein complexes involved in the epigenetic regulation of gene expression. ASXL1 mutations are found in myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). They are generally associated with signs of aggressiveness and poor clinical outcome. Because of this, a systematic determination of ASXL1 mutational status in myeloid malignancies should help in prognosis assessment.
Complete list of metadata

Cited literature [53 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-00698796
Contributor : Ed. BMC Connect in order to contact the contributor
Submitted on : Thursday, May 17, 2012 - 9:03:09 PM
Last modification on : Friday, October 22, 2021 - 3:30:51 AM
Long-term archiving on: : Friday, November 30, 2012 - 11:55:16 AM

Files

1756-8722-5-12.pdf
Publisher files allowed on an open archive

Identifiers

Collections

Citation

Véronique Gelsi-Boyer, Mandy Brecqueville, Raynier Devillier, Anne Murati, Marie-Joelle Mozziconacci, et al.. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.. Journal of Hematology and Oncology, BioMed Central, 2012, 5 (1), pp.12. ⟨10.1186/1756-8722-5-12⟩. ⟨inserm-00698796⟩

Share

Metrics

Record views

128

Files downloads

196